Compare JBS N.V. Class A Common Shares (JBS) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JBS N.V. Class A Common Shares vs Zimmer Biomet Holdings Inc — how do they compare? JBS N.V. Class A Common Shares trades at $13.02 (market cap $13.96B), while Zimmer Biomet Holdings Inc trades at $93.28 (market cap $17.50B). The key difference: Zimmer Biomet Holdings Inc is the larger of the two by market cap, and JBS N.V. Class A Common Shares pays the higher dividend (10.31%). Which is the better fit depends on your goals — on Pluang, investors hold JBS N.V. Class A Common Shares for 0 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| JBS | ZBH | |
|---|---|---|
Market Cap | $13.96B | $17.50B |
Volume | 5,326,589 | 1,890,029 |
Sector | Consumer Staples | Health |
52-Week High | $18.42 | $103.98 |
52-Week Low | $10.86 | $79.58 |
Typical Hold Time | 0 Days | 89 Days |
Enterprise Value | $34.93B | $24.57B |
Dividend Yield | 10.31% | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBS trades at $12.93, up 0.54% today, with a neutral technical signal and strong analyst buy consensus. The stock shows attractive valuation with a P/E of 12.08 and P/S of 0.47, though recent quarterly EPS misses and a declining profit margin to 1.22% in 2026 highlight earnings pressure. Recent news includes a proposal to acquire full control of Pilgrim's Pride and a joint venture in Southeast Asia, indicating strategic expansion.
The outlook is mixed: analyst targets suggest ~40% upside to $18.17, but risks include execution on acquisitions, margin compression, and volatile beef markets. Cash flow turned positive in 2026 projections, supporting growth initiatives, yet debt levels and competitive pressures warrant caution for investors seeking stability.
Zimmer Biomet (ZBH) trades at $92.08, showing modest daily movement with a slight 0.1% decline. The stock maintains a bullish technical outlook with strong moving average signals, though RSI levels indicate potential overbought conditions near-term. Fundamentally, the company demonstrates consistent revenue growth with Q2 2026 earnings beating estimates at $2.07 per share, while maintaining healthy gross margins of 69.87%. Recent corporate developments include leadership promotions in the Americas region and a declared quarterly dividend of $0.24 per share.
ZBH presents a balanced investment case with analyst consensus pointing to 12% upside to the $103.11 price target. The medical technology leader benefits from steady procedure demand and product adoption, though investors face risks from elevated debt levels and competitive pressures. With 40% of analysts rating the stock a Buy and institutional ownership expanding, the outlook remains positive despite margin compression concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JBS N.V. Class A Common Shares
JBS N.V. is a protein-processing company producing beef, pork, poultry, lamb, fish, and plant-based products, headquartered in São Paulo and Amsterdam. It operates more than 250 production facilities across over 16 countries under brands including Friboi, Seara, Swift, and Pilgrim's, and is the majority shareholder of Pilgrim's Pride Corporation.
Read more on JBS →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
